drugset / Trial / NCT00004223

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

NCT00004223 ↗

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of docetaxel and gemcitabine in treating patients who have progressive regional or metastatic bladder cancer.

Timeline

Start
2000-02-24
Primary completion
2002-10
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 40 mg/m2 Intravenous
Subject Gemcitabine Small molecule 800 mg/m2 Intravenous